Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Head & Neck 2Gastrointestinal 2Breast 2Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Temozolomide 59Radiotherapy 37Magnetic Resonance Spectroscopy 32Radiosurgery 27Specimen Handling 23Cyclophosphamide 21pembrolizumab 20Nivolumab 20Radiation 17Carboplatin 12Biopsy 12Bevacizumab 11Vincristine 10Ipilimumab 10Cisplatin 10X-Rays 9Lomustine 8Irinotecan 8Immunoglobulin G 8Etoposide 8trametinib 7Disulfides 7AZD 6244 7pertuzumab 6atezolizumab 6abemaciclib 6Topotecan 6Proton Therapy 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × budigalimab × CNS × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡